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Abstract: This chapter reviews results of research carried out by Basak and collaborators during the past four decades or so in the development 
of novel mathematical chemodescriptors and their applications in quantitative structure-activity relationship (QSAR) studies related to the 
prediction of toxicities and bioactivities of chemicals. For chemodescriptors based QSAR studies, we have used graph theoretical, three 
dimensional (3-D), and quantum chemical indices. The graph theoretic chemodescriptors fall into two major categories: (a) Numerical invariants 
defined on simple molecular graphs representing only the adjacency and distance relationship of atoms and bonds; such invariants are called 
topostructural (TS) indices; (b) Topological indices derived from weighted molecular graphs, called topochemical (TC) indices. Collectively, the 
TS and TC descriptors are known as topological indices (TIs). The set of independent variables used for modeling also includes a group of three-
dimensional (3-D) molecular descriptors. Semi-empirical and various levels of ab initio quantum chemical indices have also been used for 
hierarchical QSAR (HiQSAR) modeling. Results indicate that in many cases of property / activity / toxicity analyzed by us, a TS + TC combination 
explains most of the variance in the data. 
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N order to describe an aspect of holistic reality we have 
to ignore certain factors such that the remainder 
separates into facts. Inevitably, such a description is true 
only within the adopted partition of the world, that is, 
within the chosen context. 
Hans Primas 
In: Chemistry, Quantum Mechanics and Reductionism 
 
A recent trend in structural chemistry, new drug discovery, 
and environmental toxicology is the use of computed mo-
lecular structure descriptors in predicting their properties 
and bioactivities [1–7] In particular, during the past half cen-
tury or so we have witnessed an upsurge of interest in the 
use of numerical invariants derived from molecular graphs 
for quantitative structure-activity / property relationship 
(QSAR / QSPR) studies.[1–8] The structure of an assembled en-
tity, e.g., a molecule, is the pattern of relationship among its 
parts. The various concepts of molecular structure, e.g. clas-
sical valence bond representations, various chemical graph 
theoretic representations, ball and spoke model of a mole-
cule, representation of molecules by minimum energy con-
formations, representation of chemical species by Hamilto-
nian operators, are model objects[9,10] derived through 
different abstractions from the same chemical reality. In each 
instance, the equivalence class (concept or model of molec-
ular structure) is generated by selecting certain aspects while 
ignoring some unique properties of those objects.  
 The modeling process consists of selecting certain 
aspects of molecular structure while ignoring others. As 
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Bertrand Russell’s theory of knowledge: “The more, how-
ever, we tum to the most primitive concepts of everyday 
life, the more difficult it becomes amidst the mass of 
inveterate habits to recognize the concept as an inde-
pendent creation of thinking. It was thus that the fateful 
conception – fateful, that is to say, for an understanding of 
the here-existing conditions – could arise, according to which 
the concepts originate from experience by way of 
"abstraction," i.e., through omission of a part of its content.” 
 As pointed out by Basak et al[10,12] regarding the 
philosophy of modeling of molecular structure: “Any 
concept of molecular structure is a hypothetical sketch of 
the organization of molecules. Such a model object is a 
general theory and remains empirically untestable. A 
model object has to be grafted onto a specific theory to 
generate a theoretical model. A theoretical model of an 
object can be empirically tested. For example, when it was 
suggested by Sylvester[13] in 1878 that the structural 
formula of a molecule is a special kind of graph, it was an 
innovative general theory without any predictive potential. 
When the idea of combinatorics was applied on chemical 
graphs (model objects), it could be predicted that "there 
should be exactly two isomers of butane (C4H10)" because 
"there are exactly two tree graphs with four verüces" when 
one considers only the non-hydrogen atoms present in 
C4H10. This is a theoretical model of limited predictive 
potential. Although it predicts the existence of chemical 
species, given a set of molecules, e.g. isomers of hexane 
(C6H14), the model is incapable of predicting any property. 
This is because of the fact that any empirical property P 
maps a set of chemical structures into the set ʀ of real 
numbers and thereby orders the set empirically. Therefore, 
to predict the property from structure, we need a 
nonempirical (structural) ordering scheme which closely 
resembles the empirical ordering of structures as 
determined by P. This is a more specific theoretical model 
based on the same model object (chemical graph) and can 
be accomplished by using specific graph invariant(s).” 
 
MATHEMATICAL CHEMO- 
DESCRIPTORS: TOPOLOGICAL  
INDICES, 3-D DESCRIPTORS AND  
QUANTUM CHEMICAL INDICES 
As discussed in section 1 above, optimal characterization of 
structure has remained elusive. Different groups of re-
searchers have used different methods for the representa-
tion and quantification of molecular structure. In our 
quantitative structure-activity relationship (QSAR) and 
quantitative molecular similarity analysis (QMSA) research, 
we have used mainly three classes of descriptors for the 
quantification of structure, viz., (a) graph invariants defined 
on molecular graphs, also known as topological indices, (b) 
three dimensional (3-D) or geometrical descriptors, and (c) 
quantum chemical descriptors. 
 The author of this chapter (Basak) and his coworkers 
have been involved since the early 1970s in the 
development of novel numerical graph invariants or 
topological indices (TIs)[1,2] as well as biodescriptors derived 
from DNA / RNA sequences[14,15] and proteomics maps.[6,7] 
It may be mentioned here that graph theoretical numerical 
indices of molecules were called “topological indices” by 
Hosoya[16] for the first time in a paper published in 1971. 
 Our team at the University of Minnesota Duluth rou-
tinely uses the software MolconnZ,[17] POLLY,[18] Triplet[19] 
APProbe,[20] MOPAC,[21] and Gaussian[22] for the calculation 
of molecular descriptors for QSAR / QSPR studies. A typical 
list of descriptors used by us is shown in Table 1 (Supple-
mentary material). 
 Basak et al.[2] have divided the topological indices 
(TIs) into two major groups:  topostructural (TS) indices and 
topochemical (TC) indices. TS indices are calculated from 
skeletal graph models of molecules which do not distin-
guish among different types of atoms in a molecule or the 
various types of chemical bonds, e.g., single bond, double 
bond, triplet bond, etc. Thus, TS indices quantify infor-
mation regarding the connectivity, adjacency, and 
distances between vertices ignoring their distinct chemical 
nature. TC indices, on the other hand, are sensitive to both 
the pattern of connectedness of the vertices (atoms), as 
well as their chemical / bonding characteristics. Therefore, 
the TC indices are more complex and chemically informa-
tive as compared to the TS descriptors. 
 The geometrical or 3-D parameters quantify the vol-
ume, size, and shape of molecules from various models. 
The three-dimensional Wiener index calculated on the 
hydrogen-suppressed and hydrogen-filled graphs are also 
quantifiers of molecular shape and size. With respect to cal-
culation of quantum chemical descriptors, we have used 
both the AM1 semi-empirical method as well as ab initio 
calculations based on the STO-3G, 6-31G(d), 6-311G, 6-
311G(d), and aug-cc-pVTZ basis sets. 
 
THE QSAR PARADIGM 
Many physiological, pathological, toxicological, and biome-
dicinal processes are determined by interactions of small 
molecules such as endogenous ligands, drugs, xenobiotics, 
and substrates as well as inhibitors of enzymes related to 
metabolic pathways with their appropriate biological targets. 
The maintenance of the integrity and continuity of such key 
ligand-biotarget interactions is critical for the smooth func-
tioning of biological systems ranging from the single celled 
organism to the complex ecosystems. A large number of 
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enzymes / receptors in appropriate physiological compart-
ments and thereby produce effect(s) that bring a pathologi-
cally perturbed biological system back to a healthy state.[1–4] 
Biological properties of molecules, beneficial or deleterious, 
can be looked upon as the result of ligand-biotarget interac-
tions and can be expressed by the relationship: 
 
 ( , )BR f S B  (1) 
 
where BR represents the normal biological or pathological / 
toxicological response produced by the ligand (drug or 
toxicant) in the target biological system, and B represents 
the relevant biochemical part of the target system which is 
perturbed by the ligand to produce the measurable effect. 
It is believed that a major determinant of BR is the nature 
or structure (S) of the ligand. The structure becomes the 
sole determinant of the variation of the measured BR from 
one chemical to another when the biological system, B, 
remains practically the same during the course of the 
experiment and there is alternation only in the structure of 
the ligands. [Eq. 1] under such a condition approximates to: 
 
 ( )BR f S  (2) 
 
 A lot of research conducted in drug discovery, 
toxicology, environmental sciences, and biochemistry 
follows the paradigm expressed in [Eq. 2] and researchers 
attempt to decipher the effects as well as the modes, and 
mechanism(s) of action of molecules on some selected 
biotargets, which are assumed not to change significantly 
during the course of the experiment. 
 When we embark on the characterization of BR based 
on chemical structure alone following [Eq. 2], we really 
attempt to understand which characteristics of the chemical 
structure are recognized by the biomolecular target. What 
are the factors involved in recognition: Molecular size, shape, 
chirality, stereo-electronic nature or charge? Which ones are 
more important and which have a marginal impact on BR? 
This is often accomplished by the development of molecular 
descriptors, referred to by us as chemodescriptors, which 
quantify various aspects of molecular structure such as 
shape, size, symmetry, chirality, stereo-electronic nature, 
etc. using various mathematical techniques. 
 
HIERARCHICAL CLASSIFICATION  
OF DESCRIPTORS 
The combination of topological, geometrical, and quantum 
chemical chemodescriptors, and biodescriptors derived 
from proteomics, genomics, and DNA / RNA sequence 
characterization, gives a hierarchy of descriptors that  
begins with the simplest graph invariants and ends with the 
biodescriptors, which require the use of massive amounts 
of expensive and time-intensive laboratory test data (Big 
Data) (Figure 1). It should be clearly stated here that 
descriptors in the higher levels of the hierarchy are not 
necessarily superior to those placed at lower levels. The 
scheme simply shows a gradation based on the need for 
computational and laboratory resources. 
 Table 1 (supplementary material) provides a list of 
TS, TC, 3-D, and quantum chemical chemodescriptors used 
by Basak and coworkers[2,3] over the years in their QSAR and 
quantitative molecular similarity analysis (QMSA) studies. 
 
QUANTITATIVE STRUCTURE- 
ACTIVITY RELATIONSHIP (QSAR)  
STUDIES USING  
CHEMODESCRIPTORS 
Current industrialized societies routinely use a large number 
of natural and anthropogenic chemicals in the form of drugs, 
solvents, synthetic intermediates, cosmetics, herbicides, 
pesticides, etc. to maintain the lifestyle. But in many cases a 
large fraction of these chemicals do not have the 
experimental data necessary for the prediction of their 
beneficial and deleterious effects.[23] Table 2 gives a partial 
list of properties, both physicochemical and biochemical / 
pharmacological / toxicological, needed for the effective 
screening of chemicals for new drug discovery and protection 
of human as well as ecological health. Because determi-
nation of such properties for so many chemicals in the labo-
ratory is prohibitively costly, one solution of this quagmire 
has been the use of QSARs and molecular similarity based 
analogs to obtain acceptable estimated values of properties. 
Statistical Methods for QSAR Model 
Development And Validation 
In God we trust. All others must bring data. 
– W. Edwards Deming 
Figure 1. Hierarchical classification of chemodescriptors and 
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In the early 1970s, when this author (Basak) started carry-
ing out research on the development and use of calculated 
chemodescriptors in QSAR, only a few such descriptors 
were available. But now, with the availability of various 
software[17–22] the landscape of availability and calculation 
of molecular descriptors is very different. The four major 
pillars[2] of a useful QSAR system development are: 
(a) Availability of high quality experimental data 
(veracity of dependent variable) 
(b) Data on sufficient number of compounds 
(reasonably good sample size) 
(c) Availability of relevant descriptors (independent 
variables of QSAR) which quantify aspects of 
molecular structure relevant to the activity / 
toxicity of interest 
(d) Use of appropriate methods for model building 
and validation. 
 The various pathways for the development of 
structure-activity relationship (SAR) and property-activity 
relationship (PAR) models either from calculated molecular 
descriptors or from experimentally determined as well as 
calculated properties as independent variables may be 
expressed by the scheme provided in Figure 2. 
 The use of computed molecular descriptors and 
experimental property data in PAR / SAR / QSAR may be 
illuminated through a formal exposition of the structure-
property similarity principle—the central paradigm of the 
field of SAR.[24] Figure 2 depicts the determination of an 
experimental property, e.g., measurement of octanol-
water partition coefficient of a chemical in the laboratory, 
as a function α: C→R which maps the set C of compounds 
into the real line R. A non-empirical QSAR may be looked 
upon as a composition of a description function β1: C→D 
mapping each chemical structure of C into a space of non-
empirical structural descriptors (D) and a prediction func-
tion β2: D→R which maps the descriptors into the real line. 
When [α(C) – β2∘β1 (C)] is within the range of experimental 
errors, we say that we have a good QSAR model. On the 
other hand, PAR is the composition of θ1: C→M which maps 
the set C into the molecular property space M and θ2: M→R 
mapping those molecular properties into the real line R. 
Property-activity relationship seeks to predict one property 
(usually a complex physicochemical property) or bioactivity 
of a molecule in terms of other (usually simpler or easily 
determined experimentally) properties. 
 In the process of formulating a scientifically inter-
pretable and technically sound QSAR model, one needs to 
keep in mind some important issues. First and foremost, we 
have to check whether a specific method is the best tech-
nique in modeling a specific QSAR scenario. In a regression 
set up, for example, when the number of independent var-
iables or descriptors (p) is much larger than the number of 
data points (dependent variable, n) i.e. p >> n, the estimate 
of the coefficient vector is non-unique. This is also the case 
when predictors in the study are highly correlated with one 
another to the extent that the ‘design matrix’ is rank-defi-
cient. Both of these factors are relevant to QSARs. In many 
contemporary QSAR studies, the number of initial set of 
predictors typically is in the range of hundreds or 
thousands, whereas more often than not, mostly to 
manage experimental cost, the experimenter can collect 
only a much smaller number (tens or hundreds) of samples. 
This effectively makes the problem high-dimensional and 
Table 2. List of properties needed for screening of 
chemicals. 
Physicochemical Pharmacological / Toxicological 
Molar volume Macromolecular level 
Boiling point : Receptor binding (Kd) 
Melting point : Michaelis constant (Km) 
Vapor pressure : Inhibitor constant (Ki) 
Water solubility : DNA alkylation 
Dissociation constant (pKa) : Unscheduled DNA synthesis 
Partition coefficient Cell level 
: Octanol-water (log P) : Salmonella mutagenicity 
: Air-water : Mammalian cell transformation 
: Sediment-water Organism level (acute) 
Reactivity (electrophilicity) LD50 (mouse, rat) 
 LC50 (fathead minnow) 
 Organism level (chronic) 
 : Bioconcentraton factor 
 : Carcinogenicity 
 : Reproductive toxicity 
 : Delayed neurotoxicity 
 : Biodegradation profile 
 
 
Figure 2. Composition functions of various mappings for 
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rank-deficient (p >> n) in nature. Also, when a large number 
of descriptors on a set of chemicals are used to develop 
QSARs, one should expect that some predictors within a 
single class, e.g., TC descriptors, or even predictors belong-
ing to apparently different classes could be highly corre-
lated with one another. Such situations can be tackled 
either by attempting to pick important variables through 
model selection or ‘sparsity’-type approaches, e.g. forward 
selection, least absolute shrinkage and selection operator 
(LASSO),[25] adaptive LASSO,[26] or finding a lower-dimen-
sional transformation that preserves most of the infor-
mation present in the original set of descriptors, e.g., 
principal component analysis (PCA) or envelope methods.[27] 
 One also needs to check the ability of QSAR models 
in providing competent predictions on ‘similar’ datasets via 
validation on out-of-sample test sets.[28–32] For a relatively 
small sample, i.e., a small collection of compounds, this is 
done by following a leave-one-out (LOO) cross-validation 
method. For data sets with a large number of compounds, 
a more computationally economical way is to do a k-fold 
cross-validation: split the data set randomly into k (previ-
ously decided) equal subsets, take each subset in turn as 
test set and use the remaining compounds as training sets 
and use the model to obtain predictions. Comparing cross-
validation with the somewhat prevalent method in QSAR 
research of external validation, i.e. choosing a single train-
test split of compounds, it should be pointed out that in 
external validation the splits of data sets are carried out 
only once using the experimenters’ a priori knowledge or 
some subjectively chosen ad hoc criterion. But in cross-
validation the splits are chosen randomly, thus providing a 
more unbiased estimate of the general nature of the QSAR 
model. Furthermore, Hawkins et al[28] showed theoretically 
that compared to external validation, the LOO method of 
cross-validation is a better estimator of the actual predic-
tive ability of a statistical model for small datasets, while for 
large sample sizes both perform equally well. To quote 
Hawkins et al,[28] “The bottom line is that in the typical QSAR 
setting where available sample sizes are modest, holding 
back compounds for model testing is ill-advised. This frag-
mentation of the sample harms the calibration and does not 
give a trustworthy assessment of fit anyway. It is better to 
use all data for the calibration step and check the fit by 
cross-validation, making sure that the cross-validation is 
carried out correctly.” Specific drawbacks of holding out 
only one test set in the external validation method include: 
1) Structural features of the held out chemicals may not be 
included in the modeling process, resulting in a loss of 
information, 2) Predictions are made on only a subset of the 
available compounds, whereas the LOO method predicts 
the activity value for all compounds, 3) There is no scientific 
tool that can guarantee similarity between chemicals in the 
training and test sets, and 4) Personal bias can easily be 
present in the selection of the external test set. 
 In the rank-deficient QSAR development scenarios, 
special care should be taken in combining conventional 
modeling with the additional step of variable selection or 
dimension reduction. An intuitive, but frequently 
misunderstood and wrong, procedure would be to perform 
the first stage of pre-processing first, selecting important 
variables or determining the optimal transformation, and 
then using the transformed data / selected variables to 
build the predictive QSAR models and obtain predictions 
for each train-test split. The reason why this is not 
appropriate is that the data is split only after the variable 
selection / dimension reduction step is already completed. 
Essentially this method ends up using information from the 
holdout compound/ split subset to predict activity of those 
very samples. This naïve cross-validation procedure causes 
synthetic inflation of the cross-validated q2, hence 
compromises the predictive ability of the model[29–32] 
(Figure 3). A two-step approach (referred in Figure 3 as 
‘Two-deep CV’) helps avoid this tricky situation. Instead of 
doing the pre-model building step first and then taking 
multiple splits for out-of-sample prediction, for each split 
of the data the initial steps are performed only using the 
training set of compounds every time.  Because calculations 
on two different splits are not dependent on each other, for 
large data sets the increased computational demand arising 
out of the repeated variable selection can be handled using 
substantial computer resources, e.g., parallel processing.  It 
should be emphasized that the naïve cross-validation 
(naïve CV) method gives naïve or wrong q2 values whereas 
the two-deep cross-validation (two deep CV) approach 
gives us the correct or “true” q2. 
 The quality of the model, in terms of its predictive 
ability, is evaluated based on the associated q2 value, which 
is defined as: 
 2 1 (PRESS / SSTotal)q    (3) 
 
Figure 3. Difference between naïve and two-deep cross 
validation (CV) schemes (Reprinted with permission from 
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where PRESS is the prediction sum of squares and SSTotal 
is the total sum of squares. Unlike R2 which tends to 
increase upon the addition of any descriptor, q2 will 
decrease upon the addition of irrelevant descriptors, thus 
providing a reliable measure of model quality. 
Some Examples of Hierarchical QSAR 
Using Calculated Chemodescriptors 
 
BINDING AFFINITY OF DIBENZOFURANS FOR  
ARYL HYDROCARBON (AH) RECEPTOR 
Dibenzofurans constitute an important class of 
environmental contaminants that are produced as 
undesirable by-products in natural and industrial 
processes. The toxic effects of these compounds are 
thought to be mediated through binding to the aryl 
hydrocarbon (Ah) receptor. We developed HiQSAR models 
based on a set of 32 dibenzofurans with Ah receptor 
binding affinity values obtained from the literature. 
Descriptor classes used to develop the models included the 
TS, TC, 3D, and the STO-3G class of ab initio QC descriptors. 
For this data set, the initial number of descriptors 
calculated were as follows: TS = 114; TC = 248; 3D = 7, and 
QC = 6. There were 188 descriptors retained for QSAR 
formulation after removing those that were: a) Constant 
for all compounds, b) perfectly correlated with another 
descriptor, and c) Triplet indices with missing values.  
Statistical metrics for the ridge regression (RR), partial least 
square (PLS), and principal component regression (PCR) 
models are provided in Table 3. We saw that the RR models 
were superior to those developed using either PLS or PCR. 
Examining the RR metrics, it is evident that the TC and the 
TS + TC descriptors provide high quality predictive models, 
with R2cv values of 0.820 and 0.852, respectively. The  
addition of the 3-D and STO-3G QC descriptors does not 
result in significant improvement in model quality. When 
either of the 3-D or QC classes is used alone, the results are 
quite poor.  This indicates that the topological indices are 
capable of adequately quantifying those structural features 
which are relevant to the binding of dibenzofurans to the 
Ah receptor. Comparison of the experimentally determined 
binding affinity values and those predicted using the TS + 
TC descriptors and RR model is available in Table 4 
(Supplementary material). The details of this QSAR analysis 
has been published.[33] 
 
HiQSAR MODELING OF A DIVERSE SET OF  
508 CHEMICAL MUTAGENS 
TS, TC, 3D, and QC descriptors for 508 structurally diverse 
chemicals were calculated and QSARs were developed 
hierarchically using the four types of descriptors. For details 
of calculations and model building, see ref. [31], [32], and 
[34]. The method Interrelated two way clustering, ITC,[34] 
which falls under the unsupervised class of approaches,[35] 
was used for variable selection.  Table 5 gives results of 
ridge regression (RR) alone as well as those where RR was 
used after descriptors were selected by ITC. For both RR 
only and ITC + RR models the TS + TC combination gave the 
best QSARs for predicting mutagenicity of the 508 diverse 
chemicals. The addition of 3-D and QC descriptors to the set 
of independent variables made minimum or no improve-
ment in the quality of the models. Of the 508 chemicals, 
256 were mutagens and 252 were non-mutagens based on 
Ames’ Salmonella / microsome mutagenicity assay. Regard-
ing the number of indices in the various classes for this data 
set, the make-up was as follows: TS (103); TS + TC (298); 
TS+TC+3D+QC (307).[31] 
Table 3. Summary statistics for predictive Ah receptor 




RR PCR PLS RR PCR PLS 
TS 0.731 0.690 0.701 16.9 19.4 18.7 
TS+TC 0.852 0.683 0.836 9.27 19.9 10.3 
TS+TC+3D 0.852 0.683 0.837 9.27 19.9 10.2 
TS+TC+3D + STO-3G 0.862 0.595 0.862 8.62 25.4 8.67 
TS 0.731 0.690 0.701 16.9 19.4 18.7 
TC 0.820 0.694 0.749 11.3 19.1 15.7 
3D 0.508 0.523 0.419 30.8 29.9 36.4 
STO-3G 0.544 0.458 0.501 28.6 33.9 31.3 
 
 
Table 5. HiQSAR model (RR and ITC+RR) for a diverse set of 
508 chemical mutagens / non-mutagens. All four means the 






classification / % 
Sensitivity Specificity 
Model Type: RR 
TS 103 53.14 52.34 53.97 
TS + TC 298 76.97 83.98 69.84 
All four 307 77.17 84.38 69.84 
Model Type: ITC 
TS 103 66.34 73.83 58.73 
TS + TC 298 73.23 77.34 69.05 
TS + TC + 3D 301 74.80 77.34 72.22 
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QSAR OF ANTICANCER ACTIVITY OF PHENYLINDOLES 
QSARs were developed for a set of 89 phenylindole 
derivatives using TS, TC indices and atom pairs,[36] a specific 
class of substructures. Table 6 below summarizes the 
results of this modeling effort.[37] In total, 691 APs and a set 
of 369 topological indices were calculated for this data set. 
 Recent review of results of HiQSARs carried out by 
Basak and coworkers[2,38–40] using topostructural, 
topochemical, 3-D, and quantum chemical indices for 
diverse properties, e.g., acute toxicity of benzene 
derivatives, dermal penetration of polycyclic aromatic 
hydrocarbons (PAHs), mutagenicity of a congeneric set of 
amines (heteroaromatic and aromatic) and others indicate 
that in most of the above mentioned cases TS + TC 
combination of indices give reasonable predictive models. 
The addition of 3-D and quantum chemical indices after the 
use of TS and TC descriptors did very little improvement in 
model quality. 
 
How can we explain the above-mentioned  
trend in HiQSAR? 
One plausible explanation is that for the recognition of a 
receptor, e.g., the specific recognition of dibenzofuran by 
the Ah receptor, discussed above, the dibenzofuran deriva-
tives probably need some specific geometrical and stereo-
electronic arrangements or a specific pharmacophore. But 
once this minimal requirement of the recognition process 
is present in the molecule, alterations in bioactivities from 
one molecule to another in the same structural class are 
governed by more general structural features which are 
quantified reasonably well by the TS and TC indices derived 
from the conventional bonding topology of molecules and 
features like sigma bond, π bond, lone pair of electrons, 
hydrogen bond donor acidity, hydrogen bond acceptor 
basicity, etc. More studies with different groups of 
molecules with diverse bioactivities are needed to validate 
or falsity this hypothesis in line with the falsifiability 
principle of Sir Karl Popper,[41] a basic scientific paradigm in 
the philosophy of science which defines the inherent 
testability of any scientific hypothesis. 
 
TWO QSAR PARADIGMS  
Congenericity Principle versus Diversity 
Begets Diversity Principle- Analyzed 
Using Computed Mathematical 
Chemodescriptors of Homogeneous and 
Diverse Sets of Chemical Mutagens 
The well-known and age old paradigm of quantitative struc-
ture-activity relationship (QSAR) is the congenericity 
principle which states that similar structures usually have 
similar properties. But these days a lot of large and 
structurally diverse data sets of chemicals with a common 
experimental property (dependent variable) are being 
available. Starting with the same classes of descriptors we 
extracted the two subsets of statistically most significant 
predictors for the formulation of QSARs for two different 
sets of molecules: A homogeneous set of 95 amine 
mutagens and a diverse set of 508 structurally diverse 
mutagens / non-mutagens. The predictors included calcula-
ted TS, TC, geometrical, and QC indices. Whereas for the 
homogeneous amines, a small group of only 7 descriptors 
were found to be significant in model building, for the 508 
diverse set 42 descriptors were found to be statistically 
significant.[42] This preliminary and empirical study supports 
the diversity begets diversity principle of QSAR formulated 
for the first time by Basak.[2] 
 
DIFFERENTIAL QSAR  
A Computational Approach to 
Understand the Molecular Basis of  
Drug Resistance 
The development of drug resistance, the emergence of 
multiple drug-resistant (MDR) organisms in particular, is 
well documented in the medical field today.[2] This problem 
has been identified for tuberculosis,[43] Hepatitis B,[44] Influ-
enza A viruses,[45] different types of cancer cells,[46] to 
mention just a few cases. Curt et al.[47] discussed multiple 
mechanisms, e.g.; reduced drug accumulation and / or 
retention, conformational changes in and / or overpro-
duction of the biochemical target, and reduced activation 
and / or increased catabolism of drugs may be involved in 
the emergence of resistance. When resistance develops, 
the original effectiveness of the drug is gradually 
compromised. The target-ligand interaction thus altered 
may be analyzed using multiple methods including: (a) 
Characterizing the altered sensitivity of the target using 
QSARs based on computed descriptors of the ligands, and 
(b) Analyzing altered structures of the biological target and 
their impact on drug-target interaction patterns resulting in 
the observed phenomenon of resistance. 
 In probably the first study of its kind, using a set of 
58 cycloguanil derivatives tested against the dihydrofolate 
reductase (DHFR) enzyme from sensitive and mutant 
Table 6. Ridge Regression Results with TI, AP, and TI + AP for 
89 phenylindoles. 
Descriptor class q2 PRESS 
TI 0.678 13.72 
AP 0.703 12.66 
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strains of Plasmodium falciparum, Basak and Mills[48] devel-
oped QSARs for two types of DHFRs, one wild and the other 
resistant, using the same set of calculated mathematical 
descriptors. 
 When key amino acid residues in the DHFR enzyme 
sequences are altered, the parasite develops resistance to 
the antimalarial drug cycloguanil. For example, P. falciparum 
strains having a pair of point mutations from Ala-16 to  
Val-16 and from Ser-108 to Thr-108 are substantially 
resistant to cycloguanil as compared to the sensitive 
strains.[49] 
 A comparison of the first twenty most influential 
molecular descriptors from the two QSARs, based on 
sensitive and resistant DHFRs, showed that only two of the 
twenty descriptors were common between the two QSAR 
models. Such differential QSARs (DiffQSARs) using a high 
dimensional chemodescriptor space shed light on the 
manner in which ligand (cycloguanil) – target (DHFR) 
interaction was modified as a result of the mutation 
underlying resistance. Subsequently, Basak and Mills[50] 
extended this approach to five (one wild and four mutants) 
varieties of DHFRs. Such mathematical chemodescriptor 
based QSARs can help in the in silico screening of libraries 
in the design of drugs active against resistant organisms like 
P. falciparum and others mentioned above once sufficient 
test data for model building are available. 
 
APPLICABILITY DOMAIN OF  
QSAR MODELS 
A very important issue in the development of a QSAR model 
is that of defining the applicability domain (AD) of the 
model. This is necessary for any valid implementable QSAR 
model according to OECD principles.[51] There are a few 
methods of defining the AD of statistical models which can 
be roughly divided into two classes: (a) AD methods that 
define the active predictor space through some method like 
bounding box, PCA or convex hulls; and (b) Distance-based 
methods which compute the similarity / dissimilarity of a 
new compound to the set of compounds which have been 
used in formulating the training model. To obtain 
predictions for any incoming sample set using the model, 
the first group of methods are used to ensure that the 
compounds are within the so-called ‘active subspace’: 
which essentially means that we are actually performing 
interpolation only, not extrapolation.[52,53] For the distance-
based approach, a pre-defined statistic is calculated to 
quantify the degree of nearness of the test compounds to 
the training set and based on whether that statistic is above 
or below a certain cutoff value, predictions for those 
compounds are considered acceptable or not.[52,54] 
 
PRACTICAL APPLICATIONS OF  
QSAR 
Knowledge is of no value unless you put it into practice. 
– Anton Chekhov 
 
Practical applications of good quality QSARs, particularly 
those based on easily calculated molecular descriptors, can 
be very useful tools in pharmaceutical drug design, 
pollution prevention, and specialty chemical design. 
 In pharmaceutical drug design, the journey of 
identified lead molecules in the drug discovery pipeline is a 
long and risky one. Average cost of developing a new drug 
(including the cost of failures) during 2000s to early 2010s 
was US $2.6 billion.[55] One important contributing factor to 
this astronomical cost is that the drug developer has to 
produce and test a large number of derivatives of the lead 
structure for their beneficial and toxic side effects before 
one marketable drug is identified. QSAR can play a very 
important role in drug design providing a cheaper and fast 
alternative to the medium throughput in vitro and low 
throughput in vivo testing of chemicals, the latter two 
methods generally being used more frequently in the later 
stages of the discovery cascade. It has been noted that 
currently no drug is developed without going through the 
prior evaluation by QSAR methods.[56] 
 In Figure 4, a general scheme is provided for the use 
of QSAR in drug discovery. Beginning with a “lead 
compound,” modern combinatorial chemistry techniques 
can produce millions, even billions, of derivatives. Such real 
or hypothetical chemicals must be evaluated in real time to 
prioritize them for synthesis and experimental testing. 
QSARs based on easily calculated descriptors can help us in 
accomplishing this task.[2] 
 The era of “Big Data” has arrived in the realm of drug 
discovery. QSAR based on easily calculated molecular 
 
 
Figure 4. A suggested generic scheme for the use of QSARs 
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descriptors, the TS and TC graph invariants in particular, 
may find applications both in new drug discovery and risk 
assessment of environmental pollutants.[2] For a concise 
description of trends in this realm, please see Basak et al.[57] 
 Here we give some examples where TIs have been 
used for practical drug design. Galvez and coworkers[58,59] 
used topological approaches to design drugs for cancer 
chemotherapy and Alzheimer’s disease. In the 1980s the 
software POLLY and quantitative molecular similarity 
analysis (QMSA) method derived from principal 
components (PCs) calculated from 90 POLLY indices were 
installed at the Upjohn Company. They used this method – 
called the Basak method[60,61] – for the discovery of 
numerous lead structures for drugs. Another landmark 
study was by Grassy et al[62] on the rational design of 
immunosuppressive peptides without any information 
about their receptors or biochemical mechanisms of action. 
The authors used a variety of topological and shape 
descriptors in combination with an analysis of molecular 
dynamics trajectories to down select subsets of potential 
drug candidates. The lead compounds were peptides, 
derived from the heavy chain of the human leukocyte 
antigen (HLA) class I, that has the capability of modulating 
immune responses under in vitro and in vivo conditions. 
The molecule predicted to be most potent by the descriptor 
based approach was found to have an immunosuppressive 




Everything should be made as simple as possible, but not simpler. 
– Albert Einstein 
 
This chapter has presented a brief review of our research in 
the use of mathematical chemodescriptors in the 
prediction of bioactivity / toxicity of chemicals. 
 In the chemodescriptor realm, our major objective 
has been to investigate the utility of graph theoretical 
parameters, also known as topological indices, in QSAR / 
QSPR studies. At present a large number of descriptors can 
be calculated for chemicals using the currently available 
software. If the number of data points (dependent 
variables) for QSAR model building is much smaller than the 
number of descriptors, i.e., the situation is rank deficient, 
one needs to be cautious. We have discussed variable 
selection methods including ITC[34] which, to our know-
ledge, has probably been for the first time imported to 
QSAR from the genomics area in our research. In the calcul-
ation of q2 in the rank deficient case, one must follow the 
two-deep cross-validation procedure; otherwise the 
calculated q2 will reflect overfitting.[28–31] In HiQSAR 
modeling, we found that of the four types of calculated  
molecular descriptors, viz., TS, TC, 3-D, and QC indices, in 
most cases a TS + TC combination gave good quality 
models; the addition of 3-D or QC descriptors after the 
utilization of TS and TC combination did not improve the 
model quality significantly. This is a good news in view of 
the fact that we already reached the age of big data[57] and 
easily calculated indices like TS and TC descriptors, if they 
give good models in many areas, could find wide 
applications in the in silico evaluation of chemicals. The 
congenericity principle has been a major theme of QSAR 
whereby there has been a tendency in developing QSARs of 
congeneric or structurally related sets of chemicals. When 
the same property, viz., mutagenicity, of congeneric versus 
diverse sets were used to develop QSAR models, the 
congeneric set of 95 amines needed much lower number of 
significant descriptors as compared to the diverse set of 
508 molecules. This gives support to the diversity begets 
diversity principle formulated by us.[2] 
 In the post-genomic era, the omics technologies are 
generating a lot of data on the effects of chemicals, e.g., 
drugs and xenobiotics, on the genetic system, viz., tran-
scription, translation, and post-translational modification, 
of cells and tissues. We have been involved in the 
development of biodescriptors from DNA / RNA sequences 
and two-dimensional gel electrophoresis (2DE) data as well 
as mass spectrometry derived proteomics data from cells / 
tissue exposed to drugs and toxicants including nanosub-
stances. Results of our research in this area show that the 
biodescriptors developed from proteomics data are 
capable of characterizing the pharmacological / toxicolo-
gical profiles of chemicals.[2,6,7,65] Some preliminary studies 
have been carried out by us on the use of the combined set 
of chemodescriptors and biodescriptors in predicting 
bioactivity of chemicals. Further research is needed to test 
the relative effectiveness of these two classes of 
descriptors, chemodescriptors versus biodescriptors, in 
predictive pharmacology and toxicology. 
 At this juncture, after reviewing results of QSAR 
studies using computed chemodescriptors and biodescrip-
tors, we may ask: Quo Vadimus? We found that calculated 
chemodescriptors are capable of predicting and character-
izing bioactivity and toxicity as well as toxic modes of 
action[66] of chemicals. Research using different types of 
biodescriptors also showed that such descriptors derived 
from proteomics maps have reasonable power of discrimi-
nating among structurally closely related toxicants. Can we, 
at this stage, opt for either of the two classes of descriptors, 
viz., chemodescriptor or biodescriptors alone? The answer is 
no, as is evident from our models developed for predictive 
toxicology using both chemodescriptors and biodescriptors. 
Therefore, in the foreseeable future we will need integrated 
approaches combining chemodescriptors and biodescriptors 
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 As discussed by this author[67] in a recent book on 
Advances in Mathematical Chemistry and applications: 
“Mathematical chemistry or more accurately discrete 
mathematical chemistry had a tremendous growth spurt in 
the second half of the twentieth century and the same 
trend is continuing now. This growth was fueled primarily 
by two major factors: 1) Novel applications of discrete 
mathematical concepts to chemical and biological systems, 
and 2) Availability of high speed computers and associated 
software whereby hypothesis driven as well as discovery 
oriented research on large data sets could be carried out in 
a timely manner. This led to the development of not only a 
plethora of new concepts, but also various useful applica-
tions to such important areas as drug discovery, protection 
of human as well as ecological health, bioinformatics, and 
chemoinformatics. Following the completion of the Human 
Genome Project in 2003, discrete mathematical methods 
were applied to the “omics” data to develop descriptors 
relevant to bioinformatics, toxicoinformatics, and compu-
tational biology.” 
 The results of various types of QSAR / QSPR research 
using computed chemodescriptors and biodescriptors 
derived through applications discrete mathematics on 
chemical and biological systems give us hope that an 
exciting future is in waiting ahead of us.[1 2,6,7,67] 
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